ClinicalTrials.Veeva

Menu

GENSARC 2008 : Medical Economic Evaluation of the Molecular Detection by FISH (Fluorescent in Situ Hybridization) and by PCR (Polymerase Chain Reaction) of Sarcomas Specific Translocations and Amplifications .

C

Centre Hospitalier Universitaire de Nice

Status

Completed

Conditions

Sarcoma

Study type

Observational

Funder types

Other

Identifiers

NCT00847691
PSTIC GENSARC

Details and patient eligibility

About

The clinical and histological diagnosis of sarcomas is often very difficult. The identification of chromosomal and molecular anomalies, such as amplifications, deletions or fusion genes is a powerful help for establishing a correct diagnosis of sarcomas and their benign counterparts. However, the cost of the cytogenetic and molecular techniques for the detection of these alterations is often a limitation to their use. The aim of our study is to evaluate the direct cost of the molecular techniques in comparison to the cost that would be generated by an appropriate therapy and care management of the patient in case of an erroneous diagnosis.

Enrollment

350 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • patients with biopsy or excision of sarcoma (suspected or diagnosed)
  • sampling reviewed by pathologists
  • frozen sampling
  • clinical data available

Exclusion criteria

  • opposition of patient

Trial design

350 participants in 1 patient group

Sarcoma
Description:
patients with biopsy or excision of sarcoma (suspected or diagnosed)

Trial contacts and locations

8

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems